The potential application of iron chelators for the treatment of neurodegenerative diseases.
about
White matter tract integrity metrics reflect the vulnerability of late-myelinating tracts in Alzheimer's disease.Targeting chelatable iron as a therapeutic modality in Parkinson's disease.Design of iron chelators with therapeutic application.A novel antimycobacterial compound acts as an intracellular iron chelator.Effect of Systemic Iron Overload and a Chelation Therapy in a Mouse Model of the Neurodegenerative Disease Hereditary FerritinopathyCombined therapy of iron chelator and antioxidant completely restores brain dysfunction induced by iron toxicity.Molecular mechanisms linking endometriosis under oxidative stress with ovarian tumorigenesis and therapeutic modalities.Metal dyshomeostasis and inflammation in Alzheimer's and Parkinson's diseases: possible impact of environmental exposures.Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration.Regional siderosis: a new challenge for iron chelation therapy.Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson's with novel 1-hydroxypyridin-2-one metal chelators.A novel fluorescence method for determination of pFe3+.Elucidation of the interplay between Fe(II), Fe(III), and dopamine with relevance to iron solubilization and reactive oxygen species generation by catecholamines.Iron deposits in post-mortem brains of patients with neurodegenerative and cerebrovascular diseases: a semi-quantitative 7.0 T magnetic resonance imaging study.Electroanalysis of the interaction between (-)-epigallocatechin-3-gallate (EGCG) and amyloid-β in the presence of copper.Incorporation by coordination and release of the iron chelator drug deferiprone from zinc-based metal-organic frameworks.Prevention of iron- and copper-mediated DNA damage by catecholamine and amino acid neurotransmitters, l-DOPA, and curcumin: metal binding as a general antioxidant mechanism
P2860
Q30711356-FCC38A7E-0960-4D82-9A97-2823F19F8663Q33768106-768514CA-E4F5-409B-8130-1905F0A17A4FQ34258805-F2A1905D-11FF-4BD4-A576-A76D9CC60366Q35168885-4CBB9BB3-40E6-44ED-858C-6439177F20E1Q36116653-2596EFD8-3A1B-4B9C-947E-1CE4047112B0Q37439356-B64BEEB0-BA1B-4D56-9FD5-4C47C712538FQ38005210-783F8F1C-C8F5-4743-B48F-22C9BDFFA668Q38109630-F8D44AB6-3B6D-4069-8BA5-63052B58F994Q38161837-F41FE515-C280-4A90-BA14-8E62D383C0FCQ38178660-BFA68253-6757-43BC-BE74-A8D491CC524CQ38898546-32AF437B-BB9A-4479-BE48-E368BA5902C3Q44789642-42BC47BC-2E21-4FA9-B4D3-3E8E28BD2024Q46577527-2808BF8A-7FB0-48C1-88A7-AFF9AD4066ABQ50474908-AAD951B7-49F7-47D4-BCA1-791D25F70D87Q50483443-65A37BA9-AEF7-4341-AB56-07852FE24C29Q54736959-F6F2DE7F-5207-445D-A08A-35C1A341CF70Q58046816-150A7AA8-691C-4BB9-A770-0BB877DC736D
P2860
The potential application of iron chelators for the treatment of neurodegenerative diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The potential application of i ...... of neurodegenerative diseases.
@en
The potential application of i ...... of neurodegenerative diseases.
@nl
type
label
The potential application of i ...... of neurodegenerative diseases.
@en
The potential application of i ...... of neurodegenerative diseases.
@nl
prefLabel
The potential application of i ...... of neurodegenerative diseases.
@en
The potential application of i ...... of neurodegenerative diseases.
@nl
P2093
P2860
P356
P1433
P1476
The potential application of i ...... of neurodegenerative diseases
@en
P2093
Robert C Hider
Sourav Roy
Xiao Le Kong
Yong Min Ma
P2860
P304
P356
10.1039/C0MT00087F
P50
P577
2011-02-22T00:00:00Z